Literature DB >> 10329587

Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.

B Carnemolla1, P Castellani, M Ponassi, L Borsi, S Urbini, G Nicolo, A Dorcaratto, G Viale, G Winter, D Neri, L Zardi.   

Abstract

Tenascin-C exists in several polymorphic isoforms due to alternative splicing of nine fibronectin-like type III repeats. Large Tenascin-C isoforms are present in almost all normal adult tissues but are upregulated in fetal, regenerating, and neoplastic tissues. Here, we report a human antibody fragment, TN11, derived from a phage library with high affinity for the spliced repeat C and demonstrate that this repeat is undetectable in normal adult tissues, barely detectable or undetectable in breast, lung and gastric carcinomas, meningioma, and low grade astrocytoma, but extremely abundant in high grade astrocytoma (grade III and glioblastoma), especially around vascular structures and proliferating cells. The antibody appears to have potential for development of a therapeutic agent for patients with high grade astrocytoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329587      PMCID: PMC1866608          DOI: 10.1016/S0002-9440(10)65388-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

Review 2.  Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors.

Authors:  H P Erickson; M A Bourdon
Journal:  Annu Rev Cell Biol       Date:  1989

3.  An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites.

Authors:  J R Gulcher; D E Nies; L S Marton; K Stefansson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

Review 4.  How does extracellular matrix control capillary morphogenesis?

Authors:  D E Ingber; J Folkman
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

Review 5.  Stromal involvement in malignant growth.

Authors:  A van den Hooff
Journal:  Adv Cancer Res       Date:  1988       Impact factor: 6.242

6.  Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.

Authors:  A Siri; B Carnemolla; M Saginati; A Leprini; G Casari; F Baralle; L Zardi
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

7.  Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2.

Authors:  P Riva; A Arista; C Sturiale; G Moscatelli; V Tison; M Mariani; E Seccamani; S Lazzari; L Fagioli; G Franceschi
Journal:  Int J Cancer       Date:  1992-04-22       Impact factor: 7.396

Review 8.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

9.  Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.

Authors:  M A Bourdon; C J Wikstrand; H Furthmayr; T J Matthews; D D Bigner
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

10.  A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors.

Authors:  B Carnemolla; E Balza; A Siri; L Zardi; M R Nicotra; A Bigotti; P G Natali
Journal:  J Cell Biol       Date:  1989-03       Impact factor: 10.539

View more
  31 in total

Review 1.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

2.  The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Authors:  Chiara Catania; Michela Maur; Rossana Berardi; Andrea Rocca; Anna Maria Di Giacomo; Gianluca Spitaleri; Cristina Masini; Chiara Pierantoni; Reinerio González-Iglesias; Giulia Zigon; Annaelisa Tasciotti; Leonardo Giovannoni; Valeria Lovato; Giuliano Elia; Hans D Menssen; Dario Neri; Stefano Cascinu; Pier Franco Conte; Filippo de Braud
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

3.  Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Authors:  Patrizia Castellani; Laura Borsi; Barbara Carnemolla; Attila Birò; Alessandra Dorcaratto; Giuseppe L Viale; Dario Neri; Luciano Zardi
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 4.  Biological mechanisms of glioma invasion and potential therapeutic targets.

Authors:  B B Tysnes; R Mahesparan
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

Review 5.  Tenascins and the importance of adhesion modulation.

Authors:  Ruth Chiquet-Ehrismann; Richard P Tucker
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-05-01       Impact factor: 10.005

6.  Anaplastic oligo-astrocytoma occurring after resection of a cerebral cavernous malformation; malignant transformation? Case report and review on etiology.

Authors:  Tobien Schreuder; Merijn Te Lintelo; Bela Kubat; Peter Koehler
Journal:  J Neurol       Date:  2009-09-24       Impact factor: 4.849

7.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

8.  Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.

Authors:  C Goetz; P Riva; G Poepperl; F J Gildehaus; A Hischa; K Tatsch; H J Reulen
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

9.  Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Authors:  Kathrin Schwager; Manuela Kaspar; Frank Bootz; Roberto Marcolongo; Erberto Paresce; Dario Neri; Eveline Trachsel
Journal:  Arthritis Res Ther       Date:  2009-09-25       Impact factor: 5.156

10.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.